Form 4: Arcus Biosciences COO Jennifer Jarrett Sells Shares Under 10b5-1 Trading Plan

Arcus Biosciences' Chief Operating Officer, Jennifer Jarrett, executed sales of common stock on February 26 and 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jennifer Jarrett, the Chief Operating Officer of Arcus Biosciences, sold shares of common stock on February 26 and 27, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on February 22, 2023.
• On February 26, 2024, 24,555 shares were sold at a weighted average price of $20.07, with prices ranging from $20.00 to $20.15.
• On February 27, 2024, 34,070 shares were sold at a weighted average price of $20.11, with prices ranging from $20.00 to $20.29.
• Following these transactions, Jarrett directly owns 240,253 shares of Arcus Biosciences common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating stock sales by an executive. It's neutral in sentiment as it simply reports transactions.

Positives

• The sales were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, regardless of the reason for the sale.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• The stock sales could have a minor impact on shareholder sentiment, depending on how the market interprets the transactions.

Key Dates